QIPT Quote, Financials, Valuation and Earnings

Standard BioTools, Inc. has a net margin of -5.02% compared to Quipt Home Medical Corp.'s net margin of -162.05%. Quipt Home Medical Corp.'s return on equity of -9.95% beat Standard BioTools, Inc.'s return on equity of -24.44%.

Quipt Home Medical Corp. has a consensus price target of $3.83, signalling upside risk potential of 8.36%. On the other hand Standard BioTools, Inc. has an analysts' consensus of $1.65 which suggests that it could grow by 21.09%. Given that Standard BioTools, Inc. has higher upside potential than Quipt Home Medical Corp., analysts believe Standard BioTools, Inc. is more attractive than Quipt Home Medical Corp..

Quipt Home Medical Corp. has a beta of 0.507, which suggesting that the stock is 49.253% less volatile than S&P 500. In comparison Standard BioTools, Inc. has a beta of 1.264, suggesting its more volatile than the S&P 500 by 26.42%.

Quipt Home Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quipt Home Medical Corp. pays -- of its earnings as a dividend. Standard BioTools, Inc. pays out -- of its earnings as a dividend.

Quipt Home Medical Corp. quarterly revenues are $68.3M, which are larger than Standard BioTools, Inc. quarterly revenues of $19.6M. Quipt Home Medical Corp.'s net income of -$3.4M is higher than Standard BioTools, Inc.'s net income of -$31.7M. Notably, Quipt Home Medical Corp.'s price-to-earnings ratio is -- while Standard BioTools, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quipt Home Medical Corp. is 0.62x versus 3.77x for Standard BioTools, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

LENSAR, Inc. has a net margin of -5.02% compared to Quipt Home Medical Corp.'s net margin of -25.94%. Quipt Home Medical Corp.'s return on equity of -9.95% beat LENSAR, Inc.'s return on equity of -1013.45%.

Quipt Home Medical Corp. has a consensus price target of $3.83, signalling upside risk potential of 8.36%. On the other hand LENSAR, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 28.98%. Given that LENSAR, Inc. has higher upside potential than Quipt Home Medical Corp., analysts believe LENSAR, Inc. is more attractive than Quipt Home Medical Corp..

Quipt Home Medical Corp. has a beta of 0.507, which suggesting that the stock is 49.253% less volatile than S&P 500. In comparison LENSAR, Inc. has a beta of 0.695, suggesting its less volatile than the S&P 500 by 30.495%.

Quipt Home Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENSAR, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quipt Home Medical Corp. pays -- of its earnings as a dividend. LENSAR, Inc. pays out -- of its earnings as a dividend.

Quipt Home Medical Corp. quarterly revenues are $68.3M, which are larger than LENSAR, Inc. quarterly revenues of $14.3M. Quipt Home Medical Corp.'s net income of -$3.4M is higher than LENSAR, Inc.'s net income of -$3.7M. Notably, Quipt Home Medical Corp.'s price-to-earnings ratio is -- while LENSAR, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quipt Home Medical Corp. is 0.62x versus 2.33x for LENSAR, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Yijia Group Corp. has a net margin of -5.02% compared to Quipt Home Medical Corp.'s net margin of 8.38%. Quipt Home Medical Corp.'s return on equity of -9.95% beat Yijia Group Corp.'s return on equity of 55.22%.

Quipt Home Medical Corp. has a consensus price target of $3.83, signalling upside risk potential of 8.36%. On the other hand Yijia Group Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Quipt Home Medical Corp. has higher upside potential than Yijia Group Corp., analysts believe Quipt Home Medical Corp. is more attractive than Yijia Group Corp..

Quipt Home Medical Corp. has a beta of 0.507, which suggesting that the stock is 49.253% less volatile than S&P 500. In comparison Yijia Group Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Quipt Home Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Yijia Group Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quipt Home Medical Corp. pays -- of its earnings as a dividend. Yijia Group Corp. pays out -- of its earnings as a dividend.

Quipt Home Medical Corp. quarterly revenues are $68.3M, which are larger than Yijia Group Corp. quarterly revenues of $427.1K. Quipt Home Medical Corp.'s net income of -$3.4M is lower than Yijia Group Corp.'s net income of $35.8K. Notably, Quipt Home Medical Corp.'s price-to-earnings ratio is -- while Yijia Group Corp.'s PE ratio is 46.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quipt Home Medical Corp. is 0.62x versus 14.42x for Yijia Group Corp.. Usually stocks with elevated PS ratios are considered overvalued.